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Abstract
Background: Lyme neuroborreliosis (LNB), caused by the spirochete Borrelia burgdorferi (Bb), could result in cognitive
impairment, motor dysfunction, and radiculoneuritis. We hypothesized that inflammation is a key factor in LNB
pathogenesis and recently evaluated the effects of dexamethasone, a steroidal anti-inflammatory drug, and meloxicam a
non-steroidal anti-inflammatory drug (NSAID), in a rhesus monkey model of acute LNB. Dexamethasone treatment
significantly reduced the levels of immune mediators, and prevented inflammatory and/or neurodegenerative lesions in
the central and peripheral nervous systems, and apoptosis in the dorsal root ganglia (DRG). However, infected animals
treated with meloxicam showed levels of inflammatory mediators, inflammatory lesions, and DRG cell apoptosis that were
similar to that of the infected animals that were left untreated.
Methods: To address the differential anti-inflammatory effects of dexamethasone and meloxicam on neuronal and
myelinating cells of the peripheral nervous system (PNS), we evaluated the potential of these drugs to alter the levels of
Bb-induced inflammatory mediators in rhesus DRG cell cultures and primary human Schwann cells (HSC), using multiplex
enzyme-linked immunosorbent assays (ELISA). We also ascertained the ability of these drugs to modulate cell death as
induced by live Bb in HSC using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay and
the potential of dexamethasone to modulate Bb-induced apoptosis in HSC by the TUNEL assay.
Results: Earlier, we reported that dexamethasone significantly reduced Bb-induced immune mediators and apoptosis in
rhesus DRG cell cultures. Here, we report that dexamethasone but not meloxicam significantly reduces the levels of
several cytokines and chemokines as induced by live Bb, in HSC and DRG cell cultures. Further, meloxicam does not
significantly alter Bb-induced cell death in HSC, while dexamethasone protects HSC against Bb-induced cell death.
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Conclusions: These data help further explain our in vivo findings of significantly reduced levels of inflammatory
mediators, DRG-apoptosis, and lack of inflammatory neurodegenerative lesions in the nerve roots and DRG of Bb-infected
animals that were treated with dexamethasone, but not meloxicam. Evaluating the role of the signaling mechanisms that
contribute to the anti-inflammatory potential of dexamethasone in the context of LNB could serve to identify therapeutic
targets for limiting radiculitis and axonal degeneration in peripheral LNB.
Keywords: Lyme neuroborreliosis, Inflammation, Apoptosis, Dorsal root ganglia, Schwann cells, Dexamethasone,
Meloxicam
Background
Lyme disease is caused by infection with the spirochete
Borrelia burgdorferi (Bb) [1]. Nervous system involve-
ment in Lyme disease, termed Lyme neuroborreliosis
(LNB), is manifested in about 15 % of Lyme disease pa-
tients and may affect both the central and peripheral
nervous systems. Patients with LNB typically show
the neurological triad of meningitis, cranial neuritis,
and radiculoneuritis, commonly described as menin-
goradiculitis (a.k.a. Garin-Bujadoux-Bannwarth’s syn-
drome) [1–8].
Radiculitis or radiculoneuritis that presents as neuro-
genic pain along the back, radiating into the legs and
foot, with numbness and tingling in the legs, is the most
common manifestation in patients with peripheral LNB
[9–11]. Polyneuritis affecting multiple cranial nerves
may occur, presenting as facial palsy, optic neuritis and
uveitis, abnormalities in ocular, acoustic, and taste re-
flexes, and aphasia [12–16]. Pathology examinations in
patients with peripheral nervous system (PNS) Lyme dis-
ease have shown inflammation in the nerve roots and
dorsal root ganglia (DRG) and patchy multifocal axonal
loss accompanied with epineural perivascular inflamma-
tory infiltrates or perineuritis [10, 17, 18]. Patients exhi-
biting electrophysiological abnormalities indicative of
widespread axonal damage, and nerve conduction slow-
ing, with abnormal temporal dispersion consistent with
demyelinating neuropathy, have also been reported in
LNB [10, 11, 19–22].
The rhesus macaque is an accurate model of human
nervous system Lyme disease [23–27]. Infection in nerve
roots, DRG, and sensory ganglia showing varying de-
grees of necrosis, with peripheral nerve specimens show-
ing multifocal axonal degeneration and regeneration,
and nerve conduction study results consistent with
mononeuropathy multiplex have all been observed in
the rhesus monkey model of LNB [28]. Previously, we
reported that acute neurological manifestations identi-
fied histopathologically as leptomeningitis and radiculitis
were concomitant with the inflammatory response elic-
ited by the Lyme disease spirochete [27].
We hypothesized that inflammation induced by Bb is a
key factor in mediating LNB pathogenesis. We recently
evaluated the inflammatory changes in rhesus macaques
infected with Bb that were either left untreated or were
given the anti-inflammatory drug dexamethasone, a
steroid that inhibits the expression of several immune me-
diators [29] or meloxicam, the non-steroidal anti-
inflammatory drug (NSAID) that inhibits cyclooxygenase-
2 (COX-2) [30]. Importantly, dexamethasone treatment
significantly reduced the levels of immune mediators (IL-
6, IL-8, CCL2, and CXCL13) and pleocytosis in the cere-
brospinal fluid (CSF), and prevented inflammatory and/or
neurodegenerative lesions in the central and peripheral
nervous systems, and apoptosis in the DRG [31]. Infected
animals that were treated with meloxicam showed only a
significant reduction in the levels of the B cell chemokine
CXCL-13 in the CSF, but the levels of other immune me-
diators and the inflammatory lesions displayed were simi-
lar to that of infected animals that were left untreated.
Our observations suggested that dexamethasone and
meloxicam had differential anti-inflammatory effects on
Bb-induced inflammation in glial and neuronal cells.
Earlier, we reported that dexamethasone significantly re-
duced Bb-induced immune mediators and apoptosis in
rhesus DRG cell cultures [32]. To address this notion
further, we evaluated the ability of dexamethasone and
meloxicam to modulate the levels of inflammatory medi-
ators and cell death as induced by live Bb in neuronal
cells and myelinating cells of the PNS. We specifically
evaluated the potential of these drugs to alter the levels
of Bb-induced inflammatory mediators in culture super-
natants of primary rhesus DRG cell cultures and human
Schwann cells (HSC), using multiplex enzyme-linked
immunosorbent assays (ELISA). We also ascertained the
ability of these drugs to modulate cell death as induced
by live Bb in HSC using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) viability assay
and the potential of dexamethasone to modulate Bb-
induced apoptosis in HSC by the in situ terminal deoxy-
nucleotidyl transferase dUTP nick end labeling (TUNEL)
assay. Here, we report that dexamethasone but not
meloxicam significantly reduces the levels of several cy-
tokines and chemokines as induced by live Bb in HSC
and DRG cell cultures. Further, meloxicam does not sig-
nificantly alter Bb-induced cell death in HSC, while
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dexamethasone protects HSC against Bb-induced cell
death.
Methods
Growth and preparation of live spirochetes
B. burgdorferi B31 clone 5A19 spirochetes, passages 1–3
were grown in Barbour-Stoenner-Kelly (BSK) medium,
supplemented with 6 % rabbit serum (Sigma, St. Louis,
MO) and antibiotics (rifampicin at 45.4 μg/mL, phos-
phomycin at 193 μg/mL, and amphotericin at 0.25 μg/
mL) to late logarithmic phase under microaerophilic
conditions. Spirochetes were pelleted, washed using ster-
ile phosphate-buffered saline (PBS), and resuspended in
the working medium at the desired density, as previously
described [32].
Rhesus primary DRG cultures
Primary rhesus DRG cell cultures were derived from
adult rhesus DRG tissues obtained fresh at necrospy, as
described earlier [32].
HSC cultures
Cryopreserved HSC obtained from ScienCell Inc. (Carls-
bad, CA) were cultured as previously described [32].
Immunofluorescence staining and confocal microscopy
for the expression of MBP in Schwann cell cultures
Medium was removed from HSC cultures and cells
were fixed in 2 % paraformaldehyde (PFA) followed
by post-fixation permeabilization using a mixture of
ethanol:acetic acid (2:1) (Sigma) for 5 min at −20 °C
and detached from the chamber and processed for
immunofluorescence staining as previously described
[32]. Schwann cell cultures were stained for the ex-
pression of myelin basic protein (MBP), using rabbit
polyclonal anti-human MBP Clone AB 980 at 1:100
(Millipore, Billerica, MA) and the relevant secondary
antibody, goat anti-rabbit conjugated to one of the
Alexa fluorochromes, Alexa-568 (Invitrogen) at a dilu-
tion of 1:1000 as previously described [32]. The
stained and mounted slides were stored in the dark at
4 °C until they were viewed. Confocal microscopy was
performed using a Leica TCS SP2 confocal micro-
scope equipped with three lasers (Leica Microsystems,
Fig. 1 Meloxicam does not significantly alter levels of Bb-induced
cytokines and chemokine in DRG cell cultures. The effect of meloxicam
(Mel) on the levels of CCL2 (a), IL-6 (b), and IL-8 (c) as induced by
live Bb in rhesus DRG cell cultures. Data represent mean and SEM of
values from DRG cell cultures established from three adult rhesus
macaques. The one-way ANOVA and Tukey’s multiple comparison
test was used to evaluate the statistical significance between means
of data sets
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Exton, PA). Images of individual channels were
merged to obtain images containing all channels.
Evaluating the anti-inflammatory potential of dexametha-
sone and meloxicam in DRG and HSC cultures stimulated
with live Bb
Bb strain B31 5A19 passage 3 was prepared as de-
scribed above. The DRG and HSC cultures were
washed in their respective media, devoid of antibi-
otics. The Bb cells were resuspended in culture
medium devoid of antibiotics, at the desired multipli-
city of infection (MOI). Controls with no spirochetes
were also included. Prior to stimulation with live Bb,
DRG cell cultures and HSC cultures were incubated
with various concentrations of dexamethasone (water
soluble), 5, 15, and 150 μM (Sigma), or meloxicam
(water soluble), 1, 10, 50, and 100 μM (Sigma) for
2 h at 37 °C, after which they were washed and then
incubated in fresh growth medium containing the re-
spective concentrations of dexamethasone or meloxi-
cam and live Bb at a MOI of 10:1 at 37 °C. Similar
concentrations of dexamethasone as those mentioned
above have been reported to inhibit the production of
CCL2 in mice microglia [33]. Meloxicam at a concen-
tration range of 1–100 μM has been previously shown
to be effective in inhibiting COX-2 in in vitro studies
[34].
The DRG cell cultures were incubated for 24 h as
described earlier [32], while HSC cultures were incu-
bated for 48 h, post-infection, respectively, in a hu-
midified 5 % CO2 incubator, set at 37 °C. At the end
of the incubation times, culture supernatants were
Table 1 Effect of dexamethasone and meloxicam on cytokines and chemokines induced by live Bb in HSC
Immune mediator HSC medium control HSC + live Bb (10:1) HSC + live Bb + dexamethasone (150 μM) HSC + live Bb +meloxicam (100 μM)
IL-1RA 31.38 ± 0.97 84.76 ± 9.75 18.10 ± 0.97 130.09 ± 29.18
p < 0.001 p < 0.05
IL-6 266.62 ± 12.75 1420.76 ± 62.98 850.96 ± 19.09 1845.76 ± 23.87
p < 0.001 p < 0.001
IL-8 1930.90 ± 129.43 10297.62 ± 759.93 3093.81 ± 198.68 13,686.96 ± 494.18
p < 0.001 p < 0.001
IL-10 34.86 ± 1.45 89.11 ± 2.23 110.68 ± 2.08 92.04 ± 11.43
p < 0.001 ns
IL-12 p70 303.45 ± 21.69 658.21 ± 29.69 367.02 ± 15.02 767.67 ± 36.3
p < 0.001 p < 0.05
IL-15 6.56 ± 0.58 23.67 ± 2.54 11.42 ± 1.34 38.49 ± 3.82
p < 0.001 p < 0.001
CCL2/MCP-1 885.83 ± 51.57 3227.74 ± 153.35 835.10 ± 25.57 4719.75 ± 212.96
p < 0.001 p < 0.001
CCL-5/RANTES 3.65 ± 0.7 38.19 ± 3.79 8.49 ± 1.79 47.99 ± 3.76
p < 0.001 p < 0.01
PDGF 5.65 ± 1.04 37.84 ± 4.07 14.69 ± 1.74 40.38 ± 3.47
p < 0.001 ns
IFN-γ 34.95 ± 5.48 86.33 ± 9.31 38.59 ± 3.54 112.06 ± 15.18
p < 0.001 ns
IP-10 18.94 ± 2.75 856.47 ± 73.95 365.94 ± 24.53 853.49 ± 52.38
p < 0.001 ns
G-CSF 511.26 ± 56.98 3032.42 ± 116.01 1725.49 ± 65.32 3410.18 ± 97.08
p < 0.001 p < 0.05
VEGF 1088.41 ± 162.82 5925.06 ± 195.08 2920.06 ± 130.67 6943.79 ± 172.48
p < 0.001 p < 0.001
TNF 5.24 ± 0.9 22.22 ± 2.79 8.15 ± 1.87 24.02 ± 2.69
p < 0.001 ns
Cytokines and chemokines in HSC culture supernatants after 48 h of incubation with live Bb (MOI 10:1). Data represent mean (pg/ml) and SD of triplicate
evaluations (p values represent significance for comparisons of values for Bb and Bb + Dex 150 μM or Bb and Bb +Mel 100 μM and ns not significant)
Ramesh et al. Journal of Neuroinflammation  (2015) 12:240 Page 4 of 12
Fig. 2 (See legend on next page.)
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collected for evaluation of inflammatory mediators.
Culture supernatants were centrifuged at 4 °C at
2000×g to remove any suspended bacteria, and the
supernatant was aliquoted and stored at −70 °C until
used.
Evaluation of immune mediators from culture
supernatants
The concentrations of cytokines and chemokines
present in the culture supernatants from rhesus DRG
were quantified using the MilliPlex MAP Non-Human
Primate Cytokine Magnetic Bead Panel—Premixed 23
Plex, Cytokine-Chemokine Array kit (Millipore), fol-
lowing the manufacturer’s instructions. The analytes
detected by this panel are G-CSF, GM-CSF, IFN-γ, IL-
10, IL-12/23 (p40), IL-13, IL-15, IL-17, IL-18, IL-1ra,
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, CCL2, CCL3,
CCL4, TGF-α, TNF, VEGF, and sCD40L. The concen-
trations of cytokines and chemokines present in the
culture supernatants from HSC cultures described
above were quantified using the Bio-Plex Pro™ Human
Cytokine 27-plex Assay (BioRad, Hercules, CA). The
analytes detected by this panel are FGF basic,
Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70),
IL-13, IL-15, IL-17, IP-10, MCP-1 (CCL-2), MIP-
1alpha, MIP-1beta, PDGF-BB, RANTES, TNF, and
VEGF. The multiplex plate was read using a Bio-Plex
200 Suspension Array Luminex System (Bio-Rad).
Evaluation of the ability of live Bb spirochetes to induce
HSC death by the MTT cell viability assay
HSC cell cultures were seeded as described earlier
[32] on poly-L-Lysine-coated 6-well plates and main-
tained in growth medium for 48 h. Cultures were in-
cubated with live Bb at MOI of 5:1, 10:1, and 50:1
or left in medium alone for a period of 48 h, after
which viability of HSC was evaluated by the MTT
cell viability assay using the tetrazolium dye MTT as
a substrate, and conducted according to manufac-
turer’s protocols (Sigma). Briefly, 5 mg/mL of MTT
reagent was added at a volume corresponding to
10 % of the volume of medium in the wells and in-
cubated at 37 °C, 5 % CO2 for 2 h. Cells were solu-
bilized using the “solubilization solution” and the
optical density of the resulting colored solution was
read at 570 nm, spectrophotometrically.
Evaluation of HSC apoptosis by the in situ TUNEL assay
Cells contained in chamber slides were labeled for MBP
by immunofluorescence staining as described above.
Slides were then fixed with 2 % PFA, washed three times
with PBS by rinsing slides with PBS and holding them in
PBS for 2 min between washes. Slides were then sub-
jected to the TUNEL-ApopTagPlus fluorescein in situ
apoptosis assay (Chemicon, Temecula, CA) as per the
manufacturer’s instructions. Slides were then mounted
as described above and stored at 4 °C in the dark until
viewed. The percentage of apoptotic cells from ten fields
was evaluated from each chamber area by counting the
total number of MBP-positive cells (at least 500 cells)
from each of the chamber areas, followed by the per-
centage of cells that showed co-localization of both the
TUNEL signal and MBP expression. All counts were
made by viewing slides under a fixed magnification of
63 x (corresponding to an area of 0.05 mm2) using the
confocal microscope.
Evaluation of the protective effect of dexamethasone on
Bb-induced apoptosis in HSC cultures
HSC cell cultures were seeded as described above in
chamber slides for evaluation of apoptosis or for evalu-
ation of immune mediators and maintained in growth
medium for 48 h. Prior to stimulation with live Bb, HSC
cultures were incubated with various concentrations of
dexamethasone (5, 15, and 150 μM) for 2 h at 37 °C,
after which they were washed and then incubated in
fresh growth medium containing the respective concen-
trations of dexamethasone and live Bb at a MOI of 10:1
at 37 °C for 48 h and devoid of antibiotics.
After 48 h, culture cells were fixed, stained for MBP
by immunofluorescence staining, and evaluated for
apoptosis by the in situ TUNEL assay as described
above. Medium controls that were pretreated and then
incubated with the same respective concentrations of
dexamethasone but without the addition of live Bb were
also included.
Statistical evaluation
The one-way ANOVA and Tukey’s multiple comparison
test was used to evaluate the statistical significance
(See figure on previous page.)
Fig. 2 Dexamethasone but not meloxicam significantly reduces levels of Bb-induced cytokines and chemokines in HSC. The anti-inflammatory
effect of dexamethasone (Dex) (Ai) and meloxicam (Mel) (Aii) on the levels of CCL2 as induced by live Bb in HSC. The anti-inflammatory effect of
dexamethasone (Bi) and meloxicam (Bii) on the levels of IL-6 as induced by live Bb in HSC. The anti-inflammatory effect of dexamethasone (Cii)
and meloxicam (Ciii) on the levels of IL-8 as induced by live Bb in HSC. The one-way ANOVA and Tukey’s multiple comparison test was used to
evaluate the statistical significance between means and SD of triplicate data sets, *p < 0.05, **p < 0.01, ***p < 0.001
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between means of data sets, using Graphpad Prizm soft-
ware (Graph Pad Software Inc.) version 5.
Results
Dexamethasone but not meloxicam significantly reduces
the levels of cytokines and chemokines induced by live
Bb in rhesus DRG cell cultures
We have reported that the anti-inflammatory drug dexa-
methasone is able to significantly reduce the levels of
CCL2, IL-6, and IL-8 as induced by live Bb at a MOI of
10:1 in DRG cell cultures, after 24 h in a dose-
dependent fashion [32]. Here, we report, in contrast,
that meloxicam did not show any significant alteration
in the levels of CCL2, IL-6, and IL-8 in DRG cell cul-
tures that were exposed to live Bb at the concentrations
tested, Fig. 1a–c, respectively. Data represent mean and
SEM of values from DRG cell cultures established from
three adult rhesus macaques.
Dexamethasone but not meloxicam significantly reduces
the levels of cytokines and chemokines induced by live
Bb in HSC
Earlier, we had reported on the ability of live Bb to in-
duce CCL2, IL-6, and IL-8 in HSC [32]. Here, we report
that culture supernatants of HSC that were incubated
with live Bb at a MOI of 10:1 for 48 h show significantly
elevated levels of several cytokines and chemokines as
compared to medium controls, in addition to CCL2, IL-
6, and IL-8 when evaluated by the Pro™ Human Cyto-
kine 27-plex Assay (BioRad), as shown in Table 1. IL-8,
VEGF, CCL-2, IL-6, and G-CSF reached the highest
levels, while IP-10, IL-12, IFN-γ, IL-1RA, IL-10, IL-15,
CCL-5, PDGF, and TNF reached relatively lower levels
though significantly elevated as compared to medium
controls.
Dexamethasone but not meloxicam was able to signifi-
cantly reduce the levels of the cytokines and chemokines
in HSC, at the concentrations tested. This is shown in
Table 1. Dexamethasone (150 μM) treatment resulted in
significantly reduced levels of all of the immune media-
tors induced by live Bb, except IL-10, which showed a
significantly elevated level as compared to that induced
by Bb alone. Meloxicam treatment (100 μM) resulted in
similar or slightly elevated levels of immune mediators
Fig. 3 Dexamethasone but not meloxicam protects HSC from Bb-
induced cell death. Cell viability as assayed by the MTT viability assay
of HSC incubated with live Bb at various multiplicities of infection
for 48 h is shown in a. The effect of dexamethasone on Bb-induced
cell death as visualized by the MTT assay in HSC (b). The effect of
meloxicam on Bb-induced cell death as visualized by the MTT assay
in HSC (c). The one-way ANOVA and Tukey’s multiple comparison
test was used to evaluate the statistical significance between means
and SD of triplicate data sets, ***p < 0.001
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Fig. 4 Dexamethasone protects HSC from Bb-induced apoptosis in a dose-dependent fashion. A Graphical representation of the percent
apoptosis of HSC as induced by increasing MOI of live Bb. Representative images of the quantitative view of apoptosis after immunofluorescence
staining and visualized by confocal microscopy by the in situ TUNEL assay (green) as induced by live Bb (MOI 10:1) in HSC stained with MBP (red),
after 48 h, (Bi), Bb in the presence of 5 μM dexamethasone (Bii), 15 μM dexamethasone (Biii), and 150 μM dexamethasone (Biv), respectively. C
Graphical representation of the effect of dexamethasone on the levels of apoptosis in HSC as induced by live Bb as visualized by the in situ
TUNEL assay. The one-way ANOVA and Tukey’s multiple comparison test was used to evaluate the statistical significance between means and SD
of ten data sets (approximately 500 cells) for each condition, ***p < 0.001
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elicited in response to Bb. A graphical representation of
the dose-dependent effects of dexamethasone and
meloxicam on the levels of the CCL2, IL-6, and IL-8 is
shown in Fig. 2a–c, respectively. Data represent mean
and SD of values from triplicate evaluations. While in-
creasing concentrations of dexamethasone resulted in
the expected gradual decrease in the levels of mediators,
the effect of meloxicam was opposite, resulting in signifi-
cantly elevated levels as the concentration of this drug
was increased (Fig. 2 Ai–Cii).
Dexamethasone but not meloxicam protects HSC from
Bb-induced cell death
Live Bb induces cell death in HSC in a dose-dependent
fashion. Cell viability, as assayed by the MTT assay, of
HSC incubated with Bb at various multiplicities of infec-
tion for 48 h is shown in Fig. 3a. The optical density of
the HSC cultures as measured after incubation with the
MTT substrate corresponds to the amount of purple for-
mazan formed due to cleavage of MTT by mitochondrial
dehydrogenase present only in viable cells. As the HSC
are incubated with increasing MOI of live Bb, the optical
density is significantly reduced compared to medium
controls, signifying the increase in the proportion of
dead cells in the culture.
Incubation of HSC with live Bb at a MOI of 10:1 in
the presence of increasing concentrations of dexametha-
sone resulted in significant reduction in the amount of
cell death as visualized by the MTT assay (Fig. 3b). How-
ever, meloxicam did not significantly alter the levels of
cell death as induced by live Bb (Fig. 3c).
Dexamethasone protects HSC from Bb-induced apoptosis
in a dose-dependent fashion
Apoptosis as measured by the TUNEL assay in HSC,
with increasing MOIs of live Bb in culture is shown in
Fig. 4A. Live Bb induced enhanced levels of apoptosis at
a MOI of 5:1, as compared to that in medium controls
after 48 h in culture. Levels of apoptosis increased fur-
ther at a Bb MOI of 50:1. As we had observed that dexa-
methasone significantly reduced the levels of Bb-induced
cytokines and chemokines in HSC, we ascertained if in-
flammation had a causal role in mediating apoptosis in
HSC. We thus evaluated the effect of the anti-
inflammatory drug dexamethasone on Bb-induced apop-
tosis. A representative confocal image of HSC apoptosis
in the presence of live Bb at a MOI of 10:1 after 48 h of
incubation, as visualized by the in situ TUNEL assay, is
shown in Fig. 4Bi. The levels of protection from Bb-
induced apoptosis increased with increasing concentra-
tions of dexamethasone, 5 μM, Fig. 4Bii, 15 μM,
Fig. 4Biii, and 150 μM, Fig. 4Biv. Figure 4C shows a
graphical representation of the quantification of the
levels of dexamethasone-protection described in Fig. 4B.
Incubation of HSC with live Bb in the presence of dexa-
methasone (15 and 150 μM) resulted in significant re-
duction in the levels of apoptosis (Fig. 4C).
Discussion
The pathogenesis of Lyme disease neuropathies is not
well understood. The ability of Bb to induce cyto-
kines, chemokines, and other inflammatory mediators
in glial and neuronal cells, as well as glial and neur-
onal apoptosis has been well documented [27, 31, 32,
35–39]. Our recent observations in an in vivo model
of acute LNB in the rhesus monkey suggest that
dexamethasone and meloxicam have differential anti-
inflammatory effects on Bb-induced inflammation in
glial and neuronal cells [31]. We had previously re-
ported that dexamethasone significantly reduced Bb-
induced immune mediators and apoptosis in rhesus
DRG cell cultures [32]. In this study, we explored the
anti-inflammatory potential of meloxicam in these
cells and the effects of both dexamethasone and
meloxicam on primary HSC cultures in the presence
and absence of Bb.
Radiculitis or inflammation of the dorsal root with
neurogenic pain and altered sensory reflexes is com-
monly reported in adult patients with LNB [11]. The im-
mune mediators IL-6, IL-8, and CCL2, which we found
to be elevated in the DRG cell cultures exposed to live
Bb, play a role in modulating inflammation in addition
to the pain response [11, 40–43]. As the sensory neurons
of the DRG play a key role in the sensation of pain, in-
flammation in glial and neuronal cells and cell death in
the DRG could also contribute to pain in LNB. Under-
standing the cross-talk between neuronal and glial cells
of the PNS may prove useful in elucidating the mecha-
nisms involved in Lyme peripheral neuropathy.
Unlike dexamethasone [32], meloxicam was unable to
affect the levels of CCL2, IL-6, and IL-8 produced by
rhesus DRG cell cultures in the presence of live Bb.
These results support our in vivo findings of significantly
reduced levels of inflammatory mediators, DRG-
apoptosis, and lack of inflammatory neurodegenerative
lesions in the nerve roots and DRG of Bb-infected ani-
mals that were treated with dexamethasone, but not in
those that were treated with meloxicam [31].
An important finding of this study is that live Bb can
induce several cytokines and chemokines in HSC
(Table 1), and that dexamethasone but not meloxicam
significantly reduces all inflammatory mediators, in
addition to cell death in HSC. Interestingly, dexametha-
sone treatment resulted in increased level of the anti-
inflammatory cytokine IL-10 as compared to that in-
duced by Bb alone. This finding suggests a mechanism
of action for this drug’s anti-inflammatory properties in
our system. In addition, dexamethasone has been
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reported to down-regulate pro-inflammatory cytokines
like INF-γ and TNF, while up-regulating the levels of IL-
10 in peripheral blood mononuclear cells from uveitis
patients [44].
The relative increase in the levels of certain immune
mediators observed in HSC stimulated with live Bb in
the presence of 100 μM meloxicam (Table 1) as com-
pared to that induced by Bb alone may be due to de-
creased levels of apoptosis in the presence of meloxicam.
We detected a protective effect of meloxicam on
satellite-glial cell apoptosis in the DRG of rhesus ma-
caques inoculated in vivo with live Bb after a prolonged
time (14 weeks) post-inoculation [31].
The potential of Schwann cells to initiate the process
of Wallerian degeneration by releasing pro-inflammatory
cytokines involved in leukocyte recruitment including
CCL2, IL-8, and IL-6 has been documented [45]. The
cytokines and chemokines induced by Bb in Schwann
cells that we report here could contribute to mediating
inflammatory and apoptotic signaling cascades in these
cells and trigger mechanisms of demyelination in the
PNS similar to those of other demyelinating diseases
[46, 47]. They could also contribute to the neuritis,
axonal degeneration, and axonal regeneration seen in
peripheral LNB [9, 48–52]. The importance of cytokine/
chemokine signaling and apoptosis in the regulation of
inflammatory responses in neurodegenerative diseases is
well documented [53, 54].
The mechanism of action of meloxicam centers on the
inhibition of COX-1 and, primarily, COX-2 [34, 55],
both of which are key enzymes in the process of synthe-
sis of prostaglandins (which are mediators of inflamma-
tion). The drug itself is a less potent anti-inflammatory
as compared to dexamethasone and some other NSAIDS
[56]. A specific role for COX-2 in Bb-induced inflamma-
tion and the potential of meloxicam to modulate this ef-
fect remains to be ascertained.
While treatment with antibiotics is the first line of
defense, adjuvant treatment with steroids of patients and
animals with Lyme borreliosis has been performed, with
both beneficial [31, 57–60] and harmful outcomes [61,
62]. Therefore, the implications of the findings of the
present study with regard to the treatment of human
disease are not clear. What is known, however, is that
dexamethasone modulates numerous signaling cascades
that in turn regulate both inflammation as well as apop-
tosis [33, 63, 64]. Thus, it is possible that these signaling
pathways play a role in mediating both inflammation
and apoptosis as a result of B. burgdorferi infection in
vivo. Evaluating the role of the signaling mechanisms
that contribute to the anti-inflammatory potential of
dexamethasone in the context of LNB could serve to
identify potential therapeutic targets for limiting disease
manifestations.
Conclusions
Our results indicate that while steroids could be effective
in curbing the inflammatory responses to B. burgdorferi
in the PNS, this is not the case for NSAIDs such as
meloxicam. They also pave the way towards elucidating
the inflammatory mechanisms that are elicited by the
Lyme disease spirochete in the PNS. Such mechanisms
must be at least in part, those that are inhibited by dexa-
methasone, e.g., MAPK pathways, and likely not those
that involve the action of COX.
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